Outlook Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Outlook Therapeutics (OTLK).

Price Target Range — 12 Quarters

Analyst Consensus — 7 Analysts

4Buy

3Hold

Consensus RatingBuy# Analysts7Avg. Consensus PT$10Upside to Avg. PT+1946.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 11, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$10→$11
Aug 14, 2026	BTIG	Julian Harrison	Maintained	Buy	$4
Jul 27, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Neutral	$1→$2
Jul 27, 2026	BTIG	Julian Harrison	Upgrade	Neutral→Buy	$4
Jun 11, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$6→$10
May 18, 2026	BTIG	Julian Harrison	Downgrade	Buy→Neutral	—
Mar 11, 2026	Ascendiant Capital	Edward Woo	PT Cut	Buy	$10→$6
Feb 18, 2026	HC Wainwright & Co.	Douglas Tsao	Maintained	Neutral	$1
Feb 18, 2026	Chardan Capital	Daniil Gataulin	Maintained	Neutral	$1
Jan 5, 2026	Chardan Capital	Daniil Gataulin	PT Cut	Neutral	$3→$1
Jan 2, 2026	HC Wainwright & Co.	Douglas Tsao	PT Cut	Neutral	$1→$1
Dec 22, 2025	Ascendiant Capital	Edward Woo	PT Raise	Buy	$8→$10
Sep 30, 2025	HC Wainwright & Co.	Douglas Tsao	Maintained	Neutral	$1
Sep 22, 2025	Ascendiant Capital	Edward Woo	PT Cut	Buy	$21→$8
Aug 29, 2025	Guggenheim	Eddie Hickman	Downgrade	Buy→Neutral	—
Aug 29, 2025	HC Wainwright & Co.	Douglas Tsao	Downgrade	Buy→Neutral	$1
Aug 28, 2025	Chardan Capital	Daniil Gataulin	Maintained	Neutral	$3
Aug 15, 2025	Chardan Capital	Daniil Gataulin	Maintained	Neutral	$3
Jun 6, 2025	Ascendiant Capital	Edward Woo	PT Cut	Buy	$24→$21
Feb 24, 2025	Ascendiant Capital	Edward Woo	PT Cut	Buy	$33→$24

Analyst Ratings News

PRO
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10.5

Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $10 to $10.5.

Benzinga Newsdesk

5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In

U.S. stocks fell, but S&P 500 gained 0.4% for 3rd week. Wall Street analysts make new stock picks daily, Benzinga's data can help make better trades.

Avi Kapoor

PRO
BTIG Reiterates Buy on Outlook Therapeutics, Maintains $4 Price Target

BTIG analyst Julian Harrison reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Buy and maintains $4 price target.

Benzinga Newsdesk

Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Outlook Therapeutics (NASDAQ: OTLK) to release Q3 earnings on Aug. 14. Analysts expect a loss of 8 cents/share. Analysts rate it Neutral or Buy.

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Neutral on Outlook Therapeutics, Raises Price Target to $1.6

HC Wainwright & Co. analyst Douglas Tsao maintains Outlook Therapeutics (NASDAQ:OTLK) with a Neutral and raises the price target from $0.5 to $1.6.

Benzinga Newsdesk

This General Motors Analyst Turns Bulish; Here Are Top 5 Upgrades For Monday

Wall Street analysts upgrade GM, RIVN, OTLK, F, and MBLY. See their ratings on Benzinga's analyst ratings page before buying.

Avi Kapoor

Outlook Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Outlook Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10.5

5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In

PRO
BTIG Reiterates Buy on Outlook Therapeutics, Maintains $4 Price Target

Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

PRO
HC Wainwright & Co. Maintains Neutral on Outlook Therapeutics, Raises Price Target to $1.6

This General Motors Analyst Turns Bulish; Here Are Top 5 Upgrades For Monday

People Also Watch

People Also Watch

Outlook Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Outlook Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROAscendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10.5

5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In

PROBTIG Reiterates Buy on Outlook Therapeutics, Maintains $4 Price Target

Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

PROHC Wainwright & Co. Maintains Neutral on Outlook Therapeutics, Raises Price Target to $1.6

This General Motors Analyst Turns Bulish; Here Are Top 5 Upgrades For Monday

People Also Watch

People Also Watch

PRO
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10.5

PRO
BTIG Reiterates Buy on Outlook Therapeutics, Maintains $4 Price Target

PRO
HC Wainwright & Co. Maintains Neutral on Outlook Therapeutics, Raises Price Target to $1.6